Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block. - Wikidata - awgldk - TriplyDB

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

http://www.wikidata.org/entity/Q37464166

about

The Effects of Sugammadex on Progesterone Levels in Pregnant Rats Comparison of reversal and adverse effects of sugammadex and combination of - Anticholinergic-Anticholinesterase agents in pediatric patients.

P2860

Q35609185-ABC6739C-0310-4984-9762-CC1D09C5DFF3 Q43010324-941F9505-457D-4612-8265-50869A9C2E0A

P2860

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

http://www.wikidata.org/entity/Q37464166

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

@en

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

@nl

type

label

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

@en

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

@nl

prefLabel

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

@en

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

@nl

P1433

Q37464166-24CD2E5A-214F-42F4-8824-F5765FAEE0D1

P1476

Q37464166-8A4AC462-4EA3-457B-BA65-C4A37750A8E6

P2093

Q37464166-5704C286-7CFC-4356-AD27-972AAB95C72C

Q37464166-F07B29B2-33C0-453D-B37D-F28368493C62

P2860

Q37464166-0C645F53-46F1-4693-8153-54D6C12E722D

Q37464166-1716C864-3325-463B-B625-15A0D85934EB

Q37464166-207DD38A-7C6E-4815-A562-8D6ED7A6085A

Q37464166-2509B700-A4CA-48D5-ADFC-F94B495A70AE

Q37464166-2F943F6E-F81F-46BC-8D11-482FF4FCBDC6

Q37464166-2FFDC962-DF7C-4275-8A2D-862CBB7313D3

Q37464166-35F9B3D1-2614-4F58-A6F6-371A244A7C62

Q37464166-36ED792F-C21A-4FAA-AC48-C97915D1478B

Q37464166-3BD61492-EC2E-4D4C-8537-4FA53FB97293

Q37464166-3C875E8E-2ACC-43D1-B106-EBD91F201198

P304

Q37464166-6F915766-55C2-4604-9FEA-D4ED14449F06

P31

Q37464166-E6A03568-3C9B-417D-9A1B-6104C07BD8B1

P356

Q37464166-0FB6C96C-1621-48C1-8378-E8936883255E

P433

Q37464166-5CB1CAA5-C65A-4DAF-9085-90FF992A78EC

P478

Q37464166-73A5BD8B-7F9E-4D9A-AF6F-11616F767D2F

P577

Q37464166-236345AA-CDE3-4C58-8CE7-F36B07951988

P698

Q37464166-E23DBC95-4EE8-435A-8F21-F6C9F7E3D8D4

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.

@en

P2093

Rajinder K Mirakhur

http://www.w3.org/2001/XMLSchema#string

Rosemary M G Hogg

http://www.w3.org/2001/XMLSchema#string

P2860

Neuromuscular block

Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial

Sugammadex: another milestone in clinical neuromuscular pharmacology

A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex

The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium

Cyclodextrins in topical drug formulations: theory and practice.

Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.

Liquid chromatography/mass spectrometric bioanalysis of a modified gamma-cyclodextrin (Org 25969) and Rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969.

A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host.

Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969.

P304

599-608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.09.22

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19402771

http://www.w3.org/2001/XMLSchema#string